JP2014527083A5 - - Google Patents

Download PDF

Info

Publication number
JP2014527083A5
JP2014527083A5 JP2014530793A JP2014530793A JP2014527083A5 JP 2014527083 A5 JP2014527083 A5 JP 2014527083A5 JP 2014530793 A JP2014530793 A JP 2014530793A JP 2014530793 A JP2014530793 A JP 2014530793A JP 2014527083 A5 JP2014527083 A5 JP 2014527083A5
Authority
JP
Japan
Prior art keywords
alkoxy
cyano
nitro
alkanoyloxy
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014530793A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014527083A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/055186 external-priority patent/WO2013040227A2/en
Publication of JP2014527083A publication Critical patent/JP2014527083A/ja
Publication of JP2014527083A5 publication Critical patent/JP2014527083A5/ja
Pending legal-status Critical Current

Links

JP2014530793A 2011-09-15 2012-09-13 治療用化合物 Pending JP2014527083A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161535311P 2011-09-15 2011-09-15
US61/535,311 2011-09-15
US201261681519P 2012-08-09 2012-08-09
US61/681,519 2012-08-09
PCT/US2012/055186 WO2013040227A2 (en) 2011-09-15 2012-09-13 Therapeutic compounds

Publications (2)

Publication Number Publication Date
JP2014527083A JP2014527083A (ja) 2014-10-09
JP2014527083A5 true JP2014527083A5 (enExample) 2015-08-20

Family

ID=47019147

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014530793A Pending JP2014527083A (ja) 2011-09-15 2012-09-13 治療用化合物

Country Status (6)

Country Link
US (2) US9573906B2 (enExample)
EP (2) EP2910549A1 (enExample)
JP (1) JP2014527083A (enExample)
AU (1) AU2012308582B2 (enExample)
CA (1) CA2848540A1 (enExample)
WO (1) WO2013040227A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2848540A1 (en) 2011-09-15 2013-03-21 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Therapeutic compounds
WO2015026990A2 (en) * 2013-08-20 2015-02-26 University Of Washington Through Its Center For Commercialization Novel and specific inhibitors of cytochrome p450 26 retinoic acid hydrolase
WO2015109318A2 (en) 2014-01-17 2015-07-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Therapeutic methods
US9908856B2 (en) 2014-02-26 2018-03-06 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
DK3204357T3 (da) 2014-10-10 2022-04-04 High Force Res Limited Fluorescerende, syntetiske retinoider
WO2016140979A1 (en) 2015-03-03 2016-09-09 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
WO2016140978A1 (en) * 2015-03-03 2016-09-09 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10238655B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds
US10231947B2 (en) 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof
US10238626B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
WO2020263960A1 (en) * 2019-06-28 2020-12-30 Carl Wagner Compositions comprising a retinoid x receptor (rxr) agonist, a retinoic acid receptor (rar) agonist, or a dual rxr/rar agonist

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
DE3441788A1 (de) 1984-11-15 1986-05-15 Bayer Ag, 5090 Leverkusen Alkyl-1-cyclopropyl-1,4-dihydro-4-oxo-3-chinolincarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5962731A (en) 1992-04-22 1999-10-05 Ligand Pharmaceuticals Incorporated Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US5780676A (en) 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
ATE195716T1 (de) 1992-04-22 2000-09-15 Ligand Pharm Inc Retinoid-x rezeptor selektive verbindungen
US7655699B1 (en) 1992-04-22 2010-02-02 Eisai Inc. Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US6137002A (en) 1993-07-22 2000-10-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
WO1997012853A1 (en) * 1995-10-06 1997-04-10 Ligand Pharmaceuticals Incorporated Dimer-selective rxr modulators and methods for their use
FR2746101B1 (fr) * 1996-03-14 1998-04-30 Composes bicycliques-aromatiques
WO1998046076A1 (en) * 1997-04-11 1998-10-22 Sidney Kimmel Cancer Center Retinoid related molecules for the inhibition of endothelin-1 overproduction in disease
FR2776657B1 (fr) * 1998-03-31 2000-05-26 Cird Galderma Composes bicycliques-aromatiques et leur utilisation en medecine humaine ou veterinaire ainsi qu'en cosmetologie
KR100538417B1 (ko) * 1998-05-06 2005-12-22 갈데르마 리써어치 앤드 디벨로프먼트,에스.엔.씨. 멜라닌 생성을 촉진하는 화합물의 확인을 위한 분석법 및그 분석법에 의해 확인되는 레티노이드류 화합물
ATE365158T1 (de) * 1999-04-28 2007-07-15 Inst Med Molecular Design Inc Pyrimidincarbonsäurederivate
US6313107B1 (en) 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US6291677B1 (en) 2000-08-29 2001-09-18 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
ES2256288T3 (es) 2000-08-29 2006-07-16 Allergan, Inc. Compuestos con actividad como inhibidores de citocromo p450rai.
US6303785B1 (en) 2000-08-29 2001-10-16 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
ZA200504898B (en) 2002-12-20 2006-11-29 Pharmacia Corp Acyclic pyrazole compounds
WO2005013949A2 (en) * 2003-08-07 2005-02-17 Allergan, Inc. Method for treating cachexia with retinoid ligands
EP1541549A1 (en) 2003-12-12 2005-06-15 Exonhit Therapeutics S.A. Tricyclic hydroxamate and benzaminde derivatives, compositions and methods
US7226951B2 (en) 2003-12-17 2007-06-05 Allergan, Inc. Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
WO2005058301A1 (en) 2003-12-17 2005-06-30 Allergan, Inc. Methods for treating retinoid responsive disorders using selective inhibitors of cyp26a and cyp26b
WO2007022437A2 (en) * 2005-08-18 2007-02-22 Auspex Pharmaceuticals, Inc. Therapeutic agents for the treatment of cancer and metabolic disorders
EP2130908A3 (en) * 2006-08-29 2010-01-06 Reinnervate Limited Retinoid compounds and their use
HUE031712T2 (en) 2007-01-15 2017-08-28 Chongxi Yu Retinoids and retinoid-like compounds with positively charged water-soluble prodrugs having very high skin penetration rates
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2011006157A2 (en) * 2009-07-10 2011-01-13 Case Western Reserve University Rxr agonist compounds and methods
US9096544B2 (en) * 2009-12-23 2015-08-04 Wayne State University Therapeutic compounds
CA2790318A1 (en) 2010-02-19 2011-08-25 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acti Ng For And On Behalf Of Arizona State University Novel bexarotene analogs
JP5743129B2 (ja) 2010-04-16 2015-07-01 Dic株式会社 重合性化合物を含有する液晶組成物及びそれを使用した液晶表示素子
CA2848540A1 (en) 2011-09-15 2013-03-21 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Therapeutic compounds

Similar Documents

Publication Publication Date Title
JP2014527083A5 (enExample)
TWI567067B (zh) TrK抑制化合物
WO2014130310A1 (en) Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
JP6795517B2 (ja) 5−芳香族アルキニル基置換ベンズアミド系化合物並びにその製造方法、薬物組成物及び使用
JP2015503507A5 (enExample)
JP2019517487A5 (enExample)
JP2011529049A5 (enExample)
RU2662806C2 (ru) 4-алкинилимидазольное производное и лекарственное средство, включающее такое производное в качестве активного ингредиента
JP2019532079A5 (enExample)
JP2016525136A5 (enExample)
JP2009523760A5 (enExample)
US9233961B2 (en) Compounds and compositions for the treatment of parasitic diseases
JP2014513110A5 (enExample)
RU2015151502A (ru) Химические соединения
JP2012501327A5 (enExample)
CN110831926B (zh) 新型四氢萘基脲衍生物
JP2017505293A5 (enExample)
JP2007507494A5 (enExample)
JP2019520344A5 (enExample)
RU2011121300A (ru) Производные 1,3,4-оксадиазола и их применение для лечения диабета
JP2021046428A (ja) Nmda受容体のモジュレーターとしてのピリドピリミジノン及びその使用
JP2012518634A5 (enExample)
JP2016525104A5 (enExample)
JP2020505354A5 (enExample)
JP2011509302A5 (enExample)